AstraZeneca, Datroway and US FDA

US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
Long wait for cancer drug approvals causing 'great anguish' among patients, doctors
Canada lags behind other developed countries when it comes to the length of time it takes to approve desperately needed ...
Healio16h
FDA approves therapies for colorectal cancer, mantle cell lymphoma
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...
phillyvoice.com11h
The FDA wants to limit nicotine in cigarettes — a move that could save millions of lives
Temple pulmonologist Dr. Jamie Garfield says the proposed regulation is an effective harm reduction strategy, but suggests it ...
To combat chronic diseases, FDA proposes putting nutrition labels on front of packages
The proposed "Nutrition info box" would show customers whether products have low, medium or high levels of saturated fat, sodium and added sugars.
AbbVie secures option to license Simcere's blood cancer drug candidate
Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...